Inclusion Criteria:

1. Diagnosis of prostate adenocarcinoma on a radical prostatectomy.

2. Prior radical prostatectomy within less than 2 years from the time of first PSA rise.

3. Demonstration of biochemical recurrence based on a PSA detectable >0.03 less than 24
months after radical prostatectomy and confirmed on 2 additional tests.

4. PSA doubling time over three values must be <= 9 months for PSA >=0.4 and PSA <=10.
If PSA is >10, there is no need for PSA doubling time.

5. Karnofsky performance status (KPS) >=70%

6. Adequate organ function as defined by hemogram with haemoglobin >8.0, platelet >100
000, white blood cell >3,500, creatinine clearance >=60 cc/min and normal liver
function tests.

7. Neoadjuvant hormone therapy prior to radical prostatectomy is allowed provided that
the total duration of therapy did not exceed 6 months.

8. Subjects must have signed an informed consent document stating that they understand
the investigational or nature of the proposed treatment.

9. Subjects must be willing and able to comply with scheduled visits, treatment plans,
laboratory tests and other procedures.

Exclusion Criteria:

1. Clinical significant cardiac disease (New York Heart Association Class III/IV), or
severe debilitating pulmonary disease.

2. Uncontrolled serious active infection.

3. Anticipated duration of life less than 2 years.

4. Less than 5-year history of successful treatment for other cancers or concurrent
active non prostate cancer other than non melanoma dermatologic tumors and non-muscle
invasive bladder tumors.

5. Peripheral neuropathy >=2 grade 2

6. Concurrent experimental treatment or involvement in other clinical trials involving
drugs.

7. Other severe acute or chronic medical conditions including psychiatric diseases or
significant laboratory abnormality requiring further investigation that may cause
undue risk for the subject's safety.

8. Subjects who participated in another clinical study/received investigational product
within 30 days of screening for this study.